69
1 Autoimmune Hemolytic Anemia: Overview and Serologic Case Studies Helene DePalma, MS, MT(ASCP)SBB, CQA(ASQ) Associate Professor, CUNY-York College Clinical Laboratory Sciences Program Lead Technologist NYBC Transfusion Services

Autoimmune Hemolytic Anemia: Overview and Serologic …nybloodcenter.org/media/filer_public/2016/04/11/helene_depalma... · Autoimmune Hemolytic Anemia: Overview and Serologic Case

Embed Size (px)

Citation preview

1

Autoimmune Hemolytic Anemia: Overview and Serologic Case Studies

Helene DePalma, MS, MT(ASCP)SBB, CQA(ASQ)

Associate Professor, CUNY-York College Clinical Laboratory Sciences Program

Lead Technologist NYBC Transfusion Services

2

AUTOIMMUNE HEMOLYTIC ANEMIA

•Autoantibodies are directed against red blood cell membrane antigens –Produced against a variety of self-antigens –Follows a failure in the self/non-self

discrimination mechanism of the immune system

3

Autoantibodies • May result in ↓RBC survival and acquired immune

hemolytic anemia through: – activation of complement system – and/or removal within the reticuloendothelial

system • Identification of an autoantibody may explain

decreased RBC survival in vivo • If a patient’s RBCs are coated with autoantibody, the

patient may present with: – a serologic ABO discrepancy – a positive Rh control – a positive direct antiglobulin test (DAT)

4

Direct Antiglobulin Test (DAT)

5

DAT evaluation •Clinical picture •Clinical history

–recent transfusion –neonate, transplant, medication

•Reagent –Polyspecific (anti-IgG and anti-C3d)

•Method –tube, gel, solid phase

•Further serological work up –Antibody identification (if IAT positive) –Eluate

6

Causes of a Positive DAT

•Autoantibodies to intrinsic RBC antigens •Alloantibodies

–recent transfusion –HDFN

•Passively transfused antibodies – IVIG or Rh immune globulin (RhIg)

•Drugs •Nonspecifically adsorbed proteins •Antibodies derived from passenger lymphocytes (solid organ or HPC transplant)

7

AIHA CLASSIFICATION

• Warm autoimmune hemolytic anemia

• Cold agglutinin disease

• Mixed type autoimmune hemolytic anemia

• Paroxysmal cold hemoglobinuria

• Drug-induced hemolytic anemia

8

WHEN CAN WE EXPECT HEMOLYSIS? • Antibody class and characteristics

– Concentration, antigen affinity, ability to fix complement, thermal amplitude

– IgG antibodies are associated with extravascular hemolysis – IgM antibodies are associated with complement activation and

potentially intravascular hemolysis

• Not all autoantibodies (or positive DATs) detected are associated with hemolysis or anemia

– 1:1000-14,000 healthy blood donors have positive DATs – 1:17-100 hospitals patients have positive DATs

• Evaluation of hemolysis should include: – CBC, reticulocyte count, bilirubin, lactate dehydrogenase,

haptoglobin; peripheral blood smear; and urinalysis

9

RBC Destruction

• Immune RBC destruction may produce either compensated or uncompensated anemia –Compensated anemia: rate of RBC

production will nearly equal the rate of RBC destruction.

–Uncompensated anemia: rate of RBC destruction exceeds the rate of RBC production.

10

11

Warm Autoimmune Hemolytic Anemia (WAIHA)

• Incidence: 1/100,000 adults • DAT positive for IgG

– DAT mostly IgG only, but may be IgG+C3 and rarely C3 only

– Rarely IgA or IgM – Eluate and plasma: panagglutinin

• Antigen specificity: May have broad Rh specificity

12

WAIHA

• Extravascular hemolysis – Laboratory findings:

• Decreased H/H • Increased reticulocyte count • Increased LDH, decreased haptoglobin,

increased bilirubin • Urine negative for heme

• Disease associations – B-cell neoplasia, lymphoproliferative, collagen-

vascular diseases

13

WAIHA: Serologic findings

• Autoantibodies present in serum in 80% of patients

Positive autocontrol

14

Differential: Antibody to a high frequency antigen

Negative autocontrol

15

Further Work-Up of Positive DAT/IAT

• Elution – Removes antibodies bound to patient RBCs, – concentrates the antibodies and helps to determine

specificity

• Adsorption – “Sponge” patient RBCs are used to soak up antibodies in

serum – remaining antibodies may be alloantibodies

These processes can take many hours!!

16

Warm autoimmune hemolytic anemia: Immunohematology tests

Test Result

Direct antiglobulin test, broad spectrum

Positive

Rh Rh Rh

Eluate

Red cells

Rh Rh Rh

Serum

Direct antiglobulin test, anti-IgG Positive (90%)

Direct antiglobulin test, anti-C3 Positive (30%)

Eluate Positive - panagglutinating antoantibody

Antibody screen (serum, plasma) Positive - panagglutinating autoantibody

Complex Complex Complex

Complex Complex Complex

17

Alloimmune hemolysis transfusion reaction due to anti-K: Immunohematology tests

Test Result

Direct antiglobulin test, broad spectrum

Positive

Eluate

Red cells

Serum

Direct antiglobulin test, anti-IgG Positive

Direct antiglobulin test, anti-C3 Negative

Eluate Anti-K (eluted off of transfused, not self RBCs)

Antibody screen (serum, plasma) Anti-K

K

K

K

K

K

K K K

K

18

Elution Techniques

Acid elution kit Digitonin plus acid Heat Freeze/thaw Ether

19

Warm autoadsorption of autoantibodies

K K

K

K

Rh

K

Complex

Rh Complex

Rh Complex

Rh Complex

K

K

The patient’s serum: autoantibodies plus alloantibodies to K

The patient’s red cells: coated with autoantibodies

20

1) Wash and heat patient’s cells (56oC) to remove autoantibodies

2) Treat with ficin to enhance Rh complex exposure

Warm autoadsorption

21

Warm autoadsorption

3) Add patient’s serum to an aliquot of treated cells; incubate, then remove serum

4) Repeat with a new aliquot of patient’s treated red cells

5) Remove serum for testing

22

Alloadsorption

•Can’t do autoadsorptions in recently transfused patients

– Risk of transfused donor RBCs absorbing an alloantibody

• Instead perform alloadsorption – Use reagent RBCs with known antigen specificity to rule

out the majority of clinically significant antibodies

23

Autoantibodies and Alloantibodies

• Up to 30% of patients with RBC autoantibodies also have underlying alloantibodies

• Some centers phenotype or genotype patients

with autoantibodies and provide phenotypically matched RBCs

– C, c, E, e, K, Jka, Jkb, Fya, Fyb, S, s

24

RBC phenotype challenges

•Monoclonal reagents •Dissociate IgG from RBC before testing with IAT reagent –Chloroquine diphosphate –EGA

•Prediction of phenotype by DNA analysis

25

Transfusion Considerations •When to release least incompatible RBCs?

– Requires medical director and/or ordering physician approval

– Realize blood bank may crossmatch units in LISS or albumin to obtain compatible crossmatch

•What to explain to clinician?

– Transfused RBCs, although crossmatch incompatible, will likely have a similar lifespan as the patient’s own RBCs (assuming alloantibodies have been ruled out)

– Indications for transfusion include symptomatic anemia (compromise in cardiac or cerebral function) or unstable hematocrit

26

Warm AIHA: Treatment • Medication

– Steroids • Decrease macrophage clearance of IgG or C3b coated

RBCs; eventually decrease antibody production – IVIG

• Saturates Fc receptors on macrophages – Rituximab

• Anti-CD20; mechanism complex (plasma cells are CD20 negative)

– Other immunosuppressive drugs (cytoxan, etc) • Plasma exchange

– Large extravascular IgG distribution decrease the efficacy of plasma exchange

• Splenectomy – 50-60% response rate – Increased risk of sepsis lifelong after splenectomy

27

28

Cold Agglutinin Disease

Epidemiology: 1-2 per million incidence; typically in middle-aged or elderly patients

Associations: Lymphoproliferative disorders

Clinical features: hemoglobinuria and acrocyanosis after cold exposure

Laboratory features: anemia, reticulocytosis, autoagglutination of cooled blood samples

29

Cold Agglutinin Disease

•Chronic – Patients in 5th-8th decade of life – Often have B-cell neoplasms, CLL, or

Waldenstrom macroglobulinemia – Monoclonal (IgM) cold agglutinins

•Transient – Younger patient population – Abrupt onset, often secondary to infectious

disease (Mycoplasma pneumoniae; EBV) – Polyclonal cold agglutinins

30

Cold Agglutinin Disease is NOT:

•Raynaud’s phenomenon –Vasospasm at cool temperatures –No associated autoantibody

•Cryoglobulinemia –Monoclonal IgMs that self-associate or

associate with IgG and precipitate from solution •May be polyclonal, may be IgGs

31

Cold Agglutinin Titers

•Sample requirements – Collect sample in a prewarmed tube – Keep warm until clot retracts

•Titer is the highest serum dilution at which agglutination of RBCs in the cold is seen

– Less than 1 in 10 in healthy patients – Greater than 1 in 10,000 in patients with cold

agglutinin disease • Thermal amplitude (more than titer) predicts

severity of disease (>30C) • I or i (rarely Pr specficity)

32

4oC

I

I

I

I

I 4oC

I

I

I

I

4oC I

I

I

4oC

I

I

I

I

I 4oC

I

I

I

I

4oC

I

I

I

I

I

4oC

I

I

I

I

I

4oC

I

I

I

I

I

Low titer (1:4): common

Moderate titer (1:64): infectious mono, mycoplasma pneumonia

High titer (>1:512): cold agglutinin disease

NO HEMOLYSIS HEMOLYSIS RARE HEMOLYSIS COMMON

4oC

Cold agglutinin disease

(Antibodies preferentially bind at 4-20ºC)

33

Typical panel seen with cold reacting antibodies

• Some automated techniques omit IS phase

• Cold antibody may not be picked up until IS crossmatch.

34

Cold Antibodies

• i = EBV – Cord cells are i positive

• I = Mycoplasma

– Adult cells are I positive

• May lead to ABO discrepancy – Test i, I, A1 cells – May need to prewarm sample

• “Cold screen” typically includes:

– Group A1, B, O, I negative, and autocontrol cells • If broad thermal range

– Prewarm technique – Cold autoadsorption – REST adsorption

35

Cold agglutinin disease: Immunohematology tests

Test Result

Direct antiglobulin test, broad spectrum

Positive

Red cells

Serum

Direct antiglobulin test, anti-IgG Negative

Direct antiglobulin test, anti-C3 Strongly positive

Eluate Negative

Antibody screen (serum, plasma)

Positive - panagglutinating cold autoantibody if done at IS

4oC

I

I

I

I

I

I

I I

36

Classic Complement Pathway • IgM binds RBCs activating the classic complement pathway

•Full assembly of membrane attack complex resulting in intravascular hemolysis

•Complement activation may not be sufficient to activate full MAC assembly, complement activation only to C3 –C3 coated RBCs

•Phagocytized by macrophages (extravascular hemolysis)

•Require 500-800 C3b molecules for clearance

•May have normal life span

37

Cold Agglutinins: Pathogenesis of Autoantibody Formation

• Immune dysfunction •Antigens sharing between infectious agent and RBC (antigen mimicry)

• Infection induced antigenic changes resulting in increased antigenicity

Cold Agglutinin Disease: Treatment

•Avoid cold exposure (cold weather, cold drinks) • Immunosuppression: chorambucil, cyclophosphamide

•Treat the underlying illness! •Prednisone and splenectomy typically NOT effective

•Consider plasma exchange in severe cases

39

40

Combined Cold and Warm AIHA (Mixed AIHA)

•Serologic findings characteristic of WAIHA and has a cold agglutinin of high titer and thermal amplitude

•Both WAIHA and CAD

• IgG antibody is usually more pathogenic – Patients often present with hemolysis

41

42

Paroxysmal Cold Hemoglobinuria (PCH; Donath-Landsteiner)

•Biphasic IgG autoantibody –Binds in the cold, lyses in the warm –DAT positive only for complement –Antibody screen negative –P specificity

• Intravascular hemolysis –Often acute and severe

43

Eder et al, Immunohematology, 21 (2): 2005.

Syphilis

44

Eder et al, Immunohematology, 21 (2): 2005.

45

PCH

• Diagnosis tricky due to temperature issues

– Sample must be collected in a prewarmed tube, and transported to the blood bank in a heel warmer or cup of warm fluid

– Clot must be allowed to retract at a warm temperature

– Serum is then evaluated for antibody

46

Normal serum is a source of complement

Donath-Landsteiner Test

47

48

Proposed Unifying Theory of Drug-Induced Antibody Reactions

49

Drug-Associated Immune Hemolytic Anemia

• Hapten hypothesis (drug adsorption): Antibodies against a drug (PCN), which is RBC bound

– Negative antibody screen – DAT positive for IgG

• Eluate negative against panel RBCs • Positive against drug coated RBCs

• Immune complex: Antibodies (IgM) against a drug/plasma protein immunogenic complex

– Most common mechanism of drug-induced hemolytic anemia

– DAT positive for complement only – Serum reacts with RBCs only in the presence of

the drug (ex. quinine, quinidine)

50

Drug-Associated Immune Hemolytic Anemia (2)

•Non-immunologic protein adsorption: Membrane modification –Positive DAT without hemolysis –Cephalothin, cisplatin

•Autoantibody induction (drug independent) Induction of authentic antibodies against RBCs by the drug (methyldopa, fludarabine) –Positive DAT, with little hemolytic anemia –Stopping the drug leads to gradual

disappearance in autoantibody

51

52

Drug Induced Hemolytic Anemia is NOT Caused by Daratumumab (DarzalexTM)

•Human monoclonal anti-CD38 to treat multiple myeloma

•CD38 is expressed on many cells, including RBCs

•Anti-CD38 interferes with antibody screening by direct binding to CD38 on RBCs

– Uniform reactions with all cells – Variable strength (1-3+) depending on method

•DAT results variable •Further testing: DTT-treated RBCs; genotyping

53

Drug-Associated Immune Hemolytic Anemia

•Practical considerations:

–Stop potential offending drugs! –Convey any concerns about drugs to

reference laboratory •May need hospital pharmacy to supply offending drug for testing

Case 1 • 59-year-old white male • Diagnosis: Anemia (Hgb 6 g/dL; AIHA suspected) • No transfusion within 3 months • Preliminary laboratory testing:

– ABO/Rh: O Rh-negative – Direct antiglobulin test: Positive

Polyspecific= 3+; IgG= 3+; C3d= NEG – Antibody screening test:

Cell I IAT: 3+ Cell II IAT: 3+ Cell III IAT: 3+

Case 1: Initial Antibody Panel Rh-hr Kell Kidd Duffy Lewis MNSs P LISS Ficin

Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 37°C IAT AHG

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 0 3+ 4+

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 0 3+ 4+

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 0 3+ 4+

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 0 3+ 4+

5 + 0 + + + 0 + + + 0 + 0 + 0 + 0 + 0 0 3+ 4+

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 0 3+ 4+

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 0 3+ 4+

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 0 3+ 4+

9 + 0 0 + + 0 + + + 0 + 0 0 + 0 0 + + 0 3+ 4+

10 + 0 0 + + 0 + + 0 0 0 + 0 + + + 0 0 0 3+ 4+

Auto 0 3+ 4+

Case 1: Autoadsorbed serum tested with selected RBC panel

Rh-hr Kell Kidd Duffy Lewis MNSs P LISS Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 37°C IAT

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 0 0

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 0 0

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 0 0

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 0 0

5 + 0 + + + 0 + + + 0 + 0 + 0 + 0 + 0 0 0

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 0 0

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 0 0

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 0 0

9 + 0 0 + + 0 + + + 0 + 0 0 + 0 0 + + 0 0

10 + 0 0 + + 0 + + 0 0 0 + 0 + + + 0 0 0 0

Auto

All check cells OK

Case 1: Eluate Tested with RBC Panel

Rh-hr Kell Kidd Duffy Lewis MNSs P Eluate Last

Wash Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 IAT IAT

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 2+ 0

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 2+ 0

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 2+ 0

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 2+ 0

5 + 0 + + + 0 + + + 0 + 0 + 0 + 0 + 0 2+ 0

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 2+ 0

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 2+ 0

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 2+ 0

9 + 0 0 + + 0 + + + 0 + 0 0 + 0 0 + + 2+ 0

10 + 0 0 + + 0 + + 0 0 0 + 0 + + + 0 0 2+ 0

All check cells OK

Case 1 Interpretation:

• Warm autoantibody • Panagglutinin detected in plasma and eluate • No underlying alloantibody after autoadsorption

Case 2 • 68-year-old female • Diagnosis: CLL • Multiple RBC transfusions in the last month • Preliminary laboratory testing:

– ABO/Rh: A Rh-positive – Direct antiglobulin test: Positive

Polyspecific= 2+; IgG= 2+; C3d= NEG – Antibody screening test:

Cell I IAT: 3+ Cell II IAT: 3+ Cell III IAT: 3+

Case 2: Initial Antibody Panel Rh-hr Kell Kidd Duffy Lewis MNSs P Albumin Ficin

Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 37°C IAT AHG

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 0 3+ 4+

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 0 3+ 4+

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 1+ 3+ 4+

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 1+ 3+ 4+

5 + 0 + + + 0 + + 0 0 + 0 + 0 + 0 + 0 1+ 3+ 4+

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 0 3+ 4+

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 0 3+ 4+

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 0 3+ 4+

9 + 0 0 + + 0 + 0 + 0 + 0 0 + 0 0 + + 0 3+ 4+

10 + 0 0 + + 0 + + 0 0 0 + 0 + + + 0 0 0 3+ 4+

Auto + 0 0 + + 0 + 0 0 0 + 0 + + + 0 0 0 3+ 4+

Case 2: Alloadsorbed serum tested with selected RBC panel

Rh-hr Kell Kidd Duffy Lewis MNSs P Albumin Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 37°C IAT

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 0 0

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 0 0

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 0 2+

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 0 2+

5 + 0 + + + 0 + + 0 0 + 0 + 0 + 0 + 0 0 2+

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 0 0

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 0 0

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 0 0

9 + 0 0 + + 0 + 0 + 0 + 0 0 + 0 0 + + 0 0

10 + 0 0 + + 0 + + 0 0 0 + 0 + + + 0 0 0 0

Auto

All check cells OK

Case 2: Eluate Tested with RBC Panel

Rh-hr Kell Kidd Duffy Lewis MNSs P Eluate Last

Wash Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 IAT IAT

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 3+ 0

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 3+ 0

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 3+ 0

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 3+ 0

5 + 0 + + + 0 + + 0 0 + 0 + 0 + 0 + 0 3+ 0

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 3+ 0

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 3+ 0

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 3+ 0

9 + 0 0 + + 0 + 0 + 0 + 0 0 + 0 0 + + 3+ 0

10 + 0 0 + + 0 + + 0 0 0 + 0 + + + 0 0 3+ 0

All check cells OK

Case 2 Interpretation:

• Allo anti-E • Warm autoantibody • Panagglutinin detected in plasma and eluate

Case 3

• Diagnosis: Sepsis • Transfused 2 units a month ago • Preliminary laboratory testing: ABO/Rh: B Positive Direct antiglobulin test: Polyspecific = 2+ IgG = Negative C3d = 2+

Case 3: Serum tested with selected RBC panel

Rh-hr Kell Kidd Duffy Lewis MNSs P Albumin Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 RT IAT

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 2+ 2+

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 2+ 1+

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 2+ 1+

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 2+ 1+

5 + 0 + + + 0 + + 0 0 + 0 + 0 + 0 + 0 2+ 2+

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 2+ 1+

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 2+ 2+

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 2+ 2+

9 + 0 0 + + 0 + 0 + 0 + 0 0 + 0 0 + + 2+ 1+

10 + 0 0 + + 0 + 0 + 0 0 + 0 0 + + 0 0 2+ 1+

Auto 2+ 1+

All check cells OK

Case 3: REST adsorbed serum tested with selected RBC panel

Rh-hr Kell Kidd Duffy Lewis MNSs P Albumin Cell D C E c e K k Jka Jkb Fya Fyb Lea Leb M N S s P1 RT IAT

1 + + 0 0 + 0 + + 0 0 + + 0 0 + 0 + + 0 2+

2 + + 0 0 + + + 0 + + 0 0 + + + 0 + + 0 0

3 + 0 + + 0 0 + + + + + + 0 0 + + + 0 0 1+

4 + 0 + + 0 0 + 0 + + 0 0 0 + 0 + 0 + 0 0

5 + 0 + + + 0 + + 0 0 + 0 + 0 + 0 + 0 0 2+

6 0 0 0 + + 0 + 0 + 0 + + 0 + 0 + 0 0 0 0

7 0 0 0 + + + + + 0 + 0 0 + + + + + + 0 2+

8 0 0 0 + + 0 + + 0 + + 0 + 0 + + + + 0 2+

9 + 0 0 + + 0 + 0 + 0 + 0 0 + 0 0 + + 0 0

10 + 0 0 + + 0 + 0 + 0 0 + 0 0 + + 0 0 0 0

Auto

All check cells OK

Case 3 Interpretation

• Cold autoantibody • Anti-Jka detected

68

AIHA Take Home Messages • Evaluate all pertinent clinical information

– Evidence of hemolysis? – Transfusion or pregnancy history? – Is there a potential for alloantibodies in addition to the

autoantibody? – Diagnosis? – Medications?

• Determine if an underlying alloantibody is present • Obtain an RBC phenotype (or genotype for predicted

phenotype) • What’s in your toolkit?

– Elution kit, monoclonal reagents, enzymes, EGA • Know when to seek help!

– Send to an Immunohematology Reference Lab for specialized tests

Acknowledgements

•Beth H. Shaz, MD, Chief Medical Officer-NYBC –Sharing her slides

•Dalisay Charles-Pierre, Manager, NYBC Immunohematology Laboratory –Sharing her case studies